chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 73.0
Sex: M
Vaccine: VARZOS
Symptoms: Erythema, Rash
Clinical narrative: Information has been received from a nurse practitioner concerning a 73 year old male with a penicillin allergy who on 22-MAY-2007 was vaccinated with a first dose of Zostavax (Oka/Merck) (657675/0618U) in the left arm.  On 27-MAY-2007 (also reported as 2 days after Zostavax (Oka/Merck) injection), the patient developed a rash, erythematous patches at LUE, back and bilateral LE.  Additional information has been requested.
Age: 75.0
Sex: F
Vaccine: VARZOS, YF
Symptoms: Aphthous stomatitis, Blister, Erythema, Genital burning sensation, Genital pain
Clinical narrative: Information has been received from a registered nurse concerning a 75 year old female who on 10-APR-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  Concomitant therapy on same date included a dose of yellow fever virus vaccine.  On approximately 10-APR-2007 the patient experienced genital burning, redness, pain, blisters.  It was reported that the patient also experienced pain, redness, swelling and canker sores in her mouth.  The patient was seen at an urgent care facility.  At the time of report, the patient was not recovered.  A product quality complaint was not involved.  No further information is expected.
Age: 75.0
Sex: F
Vaccine: VARZOS, YF
Symptoms: Oedema mouth, Oral pain, Stomatitis
Clinical narrative: Information has been received from a registered nurse concerning a 75 year old female who on 10-APR-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  Concomitant therapy on same date included a dose of yellow fever virus vaccine.  On approximately 10-APR-2007 the patient experienced genital burning, redness, pain, blisters.  It was reported that the patient also experienced pain, redness, swelling and canker sores in her mouth.  The patient was seen at an urgent care facility.  At the time of report, the patient was not recovered.  A product quality complaint was not involved.  No further information is expected.
Age: 75.0
Sex: F
Vaccine: VARZOS
Symptoms: Headache, Injection site erythema, Injection site swelling, Injection site warmth, Pyrexia
Clinical narrative: Initial and follow up information has been received from a pharmacist concerning a 75 year old retired female with a history of sulfonamide allergy who on 04-JUN-2007 at approximately 14:30 was vaccinated SC in the left arm with a first dose of Zostavax (Oka/Merck) (Lot#657764/0584U).  There was no illness at the time of vaccination.  On 06-JUN-2007 the patient presented with irritation at the injection site which was red, hot, and swollen.  She also had a headache and a mild fever.  No lab studies were performed.  No further information was provided.  Additional information has been requested.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Burning sensation, Pruritus, Rash erythematous, Rash macular
Clinical narrative: Information has been received from a registered nurse concerning a 62 year old female teacher with asthma, Grave's disease, hypothyroidism, hypertension, sleep apnoea, possible seizures, possible transient ischaemic attack, haematuria, allergic reaction to antibiotics, penicillin allergy and allergies to LOMOTIL and PROMETRIUM who on 07-JUN-2007 was vaccinated SC in the left upper arm with a single first dose of Zostavax (Oka/Merck) (lot # 657764/0584U).  Concomitant therapy included aspirin, MOBIC, lisinopril-HCTZ (MSD), SYNTHROID, rizatriptan benzoate (MSD), ULTRACET as needed, ADVAIR as needed, PROVENTIL as needed, FLONASE as needed, ESTRACE and estradiol vaginal cream.  Three days after vaccination on 10-JUN-2007, the patient developed a macular, red and flat rash over the chest and legs which caused itching and burning.  The nurse was unable to determine the number of lesions.  Unspecified medical attention was sought.  At the time of the report, the patient had recovered.  Additional information is not expected.
Age: 57.0
Sex: M
Vaccine: VARZOS
Symptoms: Condition aggravated, Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 57 year old male with a history of shingles who in approximately April 2007, was vaccinated with a dose of Zostavax (Oka/Merck).  In approximately April 2007, the patient developed shingles in the cervical-thoracic area.  No further information was provided.  There was no product quality complaint involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Secondary transmission
Clinical narrative: Information has been received from a nurse practitioner concerning her mother.  The nurse practitioner reported her father was vaccinated with Zostavax (Oka/Merck) on approximately 28-MAY-2007 and her mother caught shingles from him.  The mother's outcome was not reported.  Additional information has been requested.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 67 year old female who was vaccinated with Zostavax (Oka/Merck).  Subsequently the patient experienced shingles.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Incorrect dose administered, Injection site erythema, Injection site warmth, Urticaria
Clinical narrative: Information has been received from a registered nurse concerning a female who on an unspecified date was vaccinated with a 0.5 ml dose of Zostavax (Oka/Merck).  The patient received an "allergy shot" about 24 hours prior to vaccination.  Subsequently the patient developed a raised quarter-size welt after vaccination.  The injection site was outlined in redness (3x2 inches) and it was warm to the touch.  Unspecified medical attention was sought.  The patient treated the site with ice and hydrocortisone cream.  At the time of the report the symptoms had improved and the patient was recovering.  There was no product quality complaint involved.  No further information was reported.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pain, Rash
Clinical narrative: Information has been received from a physician concerning an adult female who on an unspecified date was vaccinated with a dose of Zostavax (Oka/Merck).  Three weeks after vaccination the patient developed a rash on both forearms, the injection site had redness and tenderness.  It was unknown if the patient had a fever.  Unspecified medical attention was sought.  The physician stated that he does not believe the rash was related to Zostavax (Oka/Merck).  There was no product quality complaint involved.  No further information was provided.  Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Incorrect dose administered, Injection site rash, Injection site scab
Clinical narrative: Information has been received from a physician concerning an "over 60 year old" male who "in the last couple of days" on approximately 10-JUN-2007 was vaccinated in his arm with a "0.5" dose of Zostavax (Oka/Merck).  Concomitant therapy included prednisone 5 ml daily.  Subsequently "in the last couple of days" on approximately 10-JUN-2007 the patient developed a large scabby rash approximately an inch in diameter at the injection site on his arm.  Unspecified medical attention was sought.  There was no product quality complaint involved.  No further information was provided.  Additional information has been requested.
Sex: U
Vaccine: VARCEL, VARZOS
Symptoms: Wrong drug administered
Clinical narrative: Information has been received from a registered nurse concerning 4 children, male and female, 10 to 13 years of age, who were inadvertently vaccinated with Zostavax (Oka/Merck) (lot #657559/0462U) instead of Varivax (Oka/Merck) (MSD).  The nurse stated this was a staff error only, and there was no product quality complaint.  Attempts are being made to obtain identifying information to distinguish the individual patients mentioned in this report.  Additional information will be provided if available.
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Paraesthesia, Rash pustular
Clinical narrative: Information has been received from a female registered nurse (age not reported) who experienced "tingling, redness (unspecified location) and pustules on her left arm after administering more than one dose of Zostavax (Oka/Merck) in one day."  The nurse reported that she did not have any direct contact with the vaccine.  The outcome was not reported.  There was no product quality complaint.  Additional information has been requested.
Age: 35.0
Sex: F
Vaccine: VARZOS
Symptoms: Condition aggravated, Genital herpes, Inappropriate schedule of drug administration
Clinical narrative: Information has been received from a vaccine specialist concerning a 35 year old female with genital herpes who on 09-FEB-2007 was vaccinated with a single dose vial of Zostavax (Oka/Merck) (lot #656606/0033U), SQ.  Concomitant medication was not reported.  On 11-FEB-2007, the patient experienced a genital herpes outbreak about two days after being vaccinated with Zostavax (Oka/Merck).  It was reported that the patient had been previously diagnosed with genital herpes prior to the vaccination.  The patient sought unspecified medical attention.  At the time of reporting, the patient was recovering from the event.  There was no product quality complaint.  Follow up information indicated that the patient had recovered.  No further information is expected.
Age: 83.0
Sex: F
Vaccine: VARZOS
Symptoms: Culture, Laboratory test, Rash
Clinical narrative: Information has been received from a consumer concerning an 83 year old female with hypertension and no allergies who on 04-APR-2007 was vaccinated with a single dose of Zostavax (Oka/Merck). Concomitant therapy included DIOVAN, "CLONODINE", LASIX and VERAPAMIL ER. On 01-MAY-2007 the patient developed rash on back side of left knee. The rash continued to spread and the patient was treated with prednisone. Within 7 days the rash completely cleared up. After stopping the prednisone treatment the rash appeared on the back of patient's right shoulder and it continued to spread. The patient again was treated with prednisone and the rash cleared in the same time frame. After stopping prednisone the rash appeared on the back of patient's right leg and it was spreading. Diagnostic laboratory test of "culture tests" was undertaken. At the time of report the patient was not recovered. A product quality complaint was not involved. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Pain, Rash
Clinical narrative: Information has been received from a physician concerning a female who on approximately 16-MAY-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On approximately 30-MAY-2007, 2 weeks after vaccination the patient experienced painful rash on lower extremities.  The physician identified it as possibly being leukoplastic angitis.  Unspecified medical attention was sought.  At the time of report the patient was recovering.  A product quality complaint was not involved.  Additional information has been requested.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Secondary transmission
Clinical narrative: Information has been received from a physician concerning an approximately 50 year old female who was working as evening driver for one female patient and a day time care taker for other female patient.  It was reported that on 29-MAY-2007 both the females were vaccinated with a dose of Zostavax (Oka/Merck).  On approximately 11-JUN-2007, 2 weeks after vaccination the patient developed herpes zoster.  The patient was seen by her physician on 11-JUN-2007.  A product quality complaint was not involved.  It was reported that one of the female patient was 91 years old and relatively healthy.  Concomitant medications included COUMADIN 1 mg, 6 days/wk, "LEXIPRO" 5 mg/day, "TETIKOSYN" 250 ug/BID, "LORAZIPAN" 0.5 mg/BID, "ATTINALOL" 125 mg/day, "LOTRIL" 2.5/10 mg/day.  Other female patient was 81 years old and relatively healthy.  Concomitant medications included "LOVOXATHOL" 0.75 mg/day, alendronate sodium (MSD) 70 mg/weekly, LIPITOR 10 mg/day, EFFEXOR SR 75 mg/BID, REMERON 15 mg/day and AMBIEN per night.  Additional information has been requested.
Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Oedema peripheral
Clinical narrative: Information has been received from a nurse concerning a 76 year old female with hypertension who on 12-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On 12-JUN-2007 or 13-jun-2007 the patient developed swelling in her feet.  At the time of this report the patient had not recovered.  No medical attention was sought.  There was no other information provided.  There was no product quality complaint involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pruritus, Injection site swelling
Clinical narrative: Information has been received from a physician concerning a female who on approximately 05-JUN-2007 was vaccinated with a 0.65 ml dose of Zostavax (Oka/Merck).  On approximately 05-JUN-2007 the patient developed a red, itchy, and swollen injection site.  Unspecified medical attention was sought.  Subsequently, the patient recovered.  No further information was provided.  There was no product quality complaint involved.  Additional information has been requested.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Body temperature, Injection site pain, Injection site rash, Pruritus, Varicella
Clinical narrative: Information has been received from a 70 year old female registered nurse with allergies to morphine and "internal iodine" and with a history of reaction to "a dressing" and chickenpox at 14 years of age who on 24-MAY-2007 was vaccinated in the left upper arm with a 0.65 ml dose of Zostavax (Oka/Merck).  There was no concomitant medication.  On 07-JUN-2007 (also reported as Day 10) the patient experienced chickenpox.  The patient developed 3 pox at the injection site and injection site pain.  The rash (lesions) spread to the patient's shoulder, down her back to her legs and then her abdomen.  She had 300-500 lesions on her body.  She treated herself with BENADRYL and TYLENOL 3 at home.  She then presented to the emergency room became her primary care physician was not available.  She was diagnosed with chickenpox.  She was prescribed an "antihistamine", ULTRAM, KEFLEX and was referred for a chest x-ray.  Her maximum temperature was 99, pain was rated as 9 on a scale of 0-10 and other systemic symptoms included itching.  It was reported that the a patient had no recent exposure to chickenpox or herpes zoster.  Additional information on 11-JUL-2007 indicated that a few days after vaccination, the patient developed 3 small pox at the injection site.  About 10 days post-vaccination she developed a chickenpox rash all over her body.  As of 11-JUL-2007, her rash was somewhat better but still present.  The patient was enrolled in a program to identify of VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the OKA/Merck vaccine VZV strain.  The sample of a lesion was collected on 10-JUL-2007, lesion type a vesicle reported to be tiny scabs.  The PCR results for the specimen were negative.  No VZV was identified.  Additional information has been requested.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Viral test negative
Clinical narrative: Information has been received from a 70 year old female registered nurse with allergies to morphine and "internal iodine" and with a history of reaction to "a dressing" and chickenpox at 14 years of age who on 24-MAY-2007 was vaccinated in the left upper arm with a 0.65 ml dose of Zostavax (Oka/Merck).  There was no concomitant medication.  On 07-JUN-2007 (also reported as Day 10) the patient experienced chickenpox.  The patient developed 3 pox at the injection site and injection site pain.  The rash (lesions) spread to the patient's shoulder, down her back to her legs and then her abdomen.  She had 300-500 lesions on her body.  She treated herself with BENADRYL and TYLENOL 3 at home.  She then presented to the emergency room became her primary care physician was not available.  She was diagnosed with chickenpox.  She was prescribed an "antihistamine", ULTRAM, KEFLEX and was referred for a chest x-ray.  Her maximum temperature was 99, pain was rated as 9 on a scale of 0-10 and other systemic symptoms included itching.  It was reported that the a patient had no recent exposure to chickenpox or herpes zoster.  Additional information on 11-JUL-2007 indicated that a few days after vaccination, the patient developed 3 small pox at the injection site.  About 10 days post-vaccination she developed a chickenpox rash all over her body.  As of 11-JUL-2007, her rash was somewhat better but still present.  The patient was enrolled in a program to identify of VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the OKA/Merck vaccine VZV strain.  The sample of a lesion was collected on 10-JUL-2007, lesion type a vesicle reported to be tiny scabs.  The PCR results for the specimen were negative.  No VZV was identified.  Additional information has been requested.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from a physician concerning a 70 year old female who was vaccinated with a 0.65 ml dose of Zostavax (Oka/Merck).  It was reported that after vaccination, the patient developed soft tissue rash.  Unspecified medical attention was sought.  At the time of report the patient had recovered.  A product quality complaint was not involved.  Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a male with a history of shingles who was vaccinated with a dose of Zostavax (Oka/Merck).  It was reported that the patient developed a mild case of shingles after vaccination.  At the time of report the patient was not recovered.  Unspecified medical attention was sought.  A product quality complaint was not involved.  Additional information has been requested.
Age: 11.0
Sex: F
Vaccine: MNQ, TDAP, VARZOS
Symptoms: Anorexia, Headache, Wrong drug administered
Clinical narrative: Information has been received from a health professional concerning a 11 year old female with hyperactivity attention deficit disorder and no known allergies who on 30-APR-2007 at 16:30 was inadvertently vaccinated SC in the right arm with a first dose of Zostavax (Oka/Merck) (lot # 656413/1477F) instead of Varivax (Oka/Merck) (MSD).  Concomitant vaccination included a first dose of ADACEL (lot # C2457AA) given IM in the left deltoid and a first dose of MENACTRA (lot # U1968AA) given IM in the right deltoid.  Other concomitant therapy included ADDERALL XR 20 mg which was started on 30-APR-2007.  Three days after vaccination on 03-MAY-2007, the patient experienced a headache.  Unspecified medical attention was sought.  There was no product quality complaint involved.  Additional information indicated from the registered nurse indicated that she did not know why the patient was vaccinated with Zostavax (Oka/Merck) (lot # 656413/1477F) instead of Varivax (Oka/Merck) (MSD).  She stated that Zostavax (Oka/Merck) was kept in the freezer with no other vaccines, they were storing it for the internal medicine department.  She was not sure why the individual went to this freezer instead of the going to the correct freezer.  That same day the patient was also started on ADDERALL XR 20 mg.  The nurse reported that the patient returned to the office on 03-MAY-2007 complaining of a headache and loss of appetite.  At the exam, it was determined that the symptoms were side effects from her starting ADDERALL XR 20 mg on 01-MAY-2007 (also reported as 30-APR-2007).  The patient subsequently recovered from the headache.  She had no other complications.  Additional information has been requested.
Age: 82.0
Sex: M
Vaccine: VARZOS
Symptoms: Blister, Blood pressure, Body temperature increased, Herpes zoster, Rash
Clinical narrative: Initial and follow up information has been received from a physician concerning an 82 year old retired male who on 08-JUN-2007 15:00 was vaccinated in the right deltoid with a first dose of Zostavax (Oka/Merck) (Lot#657765/0585U). On 10-JUN-2007, at 10:00 the patient developed a rash which was diagnosed as herpes zoster. There was no other illness at the time of vaccination. There were groups of erupted vesicles and rash on T2 of the trigeminal nerve only on the right side. The patient had a blood pressure of 142/60 and temperature of 100.9 in the doctors office on 14-JUN-2007. The physician prescribed VICODIN, ZOVIRAX and LYRICA. As of 25-JUN-2007 the patient had recovered. There was no product quality complaint. Additional information is not expected.
Age: 77.0
Sex: F
Vaccine: VARZOS
Symptoms: Induration, Injection site reaction, Pruritus, Skin warm
Clinical narrative: Information has been received from a nurse practitioner concerning a 77 year old female with allergic reaction to antibiotics, clam allergy and egg allergy who on 11-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck) (657764/0584U), subcutaneously.  Concomitant therapy included lovastatin (manufacturer unknown), and DIOVAN.  The nurse practitioner reported that the patient reported to her via e-mail that she experienced injection site reaction.  As of 15-JUN-2007, the patient had a 3 inch spot on her arm that was hard, warm, and itchy.  The patient sought unspecified medical attention.  At the time of the report the patient had not recovered.  There was no product quality complaint.  Additional information has been requested. Additional information received indicated that the patient recovered after about 1 week.  Additional information is not expected.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Rash pustular
Clinical narrative: Information has been received from a nurse concerning a patient who on an unknown date, was vaccinated with a dose of Zostavax (Oka/Merck), subcutaneous. Subsequently the patient developed a mild case of shingles (a few pustules). Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site rash
Clinical narrative: Information has been received from a physician concerning a female who on an unspecified date was vaccinated SC with a 0.65 ml dose of Zostavax (Oka/Merck). Subsequently the patient experienced a rash around the injection site. Unspecified medical attention was sought. There were no lab tests performed. There was no product quality complaint involved. No further information is available.
Age: 12.0
Sex: F
Vaccine: VARZOS
Symptoms: No adverse reaction, Wrong drug administered
Clinical narrative: Information has been received from a licensed practical nurse concerning a 12 year old female who on 15-JUN-2007 was vaccinated SC in the right deltoid with a first dose of Zostavax (Oka/Merck) (lot # 656607/0163U) instead of the second dose of Varivax (MSD) that she was scheduled to receive.  This was reported to be human error and not product confusion.  Unspecified medical attention was sought.  The patient's mother stated that the patient had no reaction.  There was no product quality complaint involved.  Additional information is not expected.  The patient's siblings had similar experiences with vaccination (WAES # 0707USA01865 and 0707USA01867).
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Inappropriate schedule of drug administration, Oral herpes
Clinical narrative: Information has been received concerning a 59 year old female with a history of cold sores and no drug reactions/allergies who on approximately 08-JUN-2007 was vaccinated SC with Zostavax (Oka/Merck) (lot #657676/0619U). There was no concomitant medication. On 15-JUN-2007, about 1 week after receiving Zostavax (Oka/Merck), the patient developed a cold sore. Unspecified medical attention was sought. There were no labs performed. The patient's cold sores persisted. No further information is available.
Age: 70.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Pain
Clinical narrative: Information has been received from a 70 year old male with Parkinson's disease and no allergies who on 01-APR-2007 was vaccinated with a dose of Zostavax (Oka/Merck). Concomitant therapy included LORTAB, amitriptyline hydrochloride (MSD) and "LIQUIP.". On 15-JUN-2007, the patient developed breakthrough shingles. The shingles were on the left side of his head and neck. The scabs went away but the pain was still present. Unspecified medical attention was sought. No diagnostic laboratory tests were performed. At the time of the report, the patient had not recovered. A product quality complaint was not involved. Additional information has been received from a nurse who reported that the patient recovered on an unspecified date. No further information is expected.
Age: 69.0
Sex: F
Vaccine: VARZOS
Symptoms: Back pain, Erythema, Skin lesion
Clinical narrative: Information has been received from a nurse practitioner concerning a 69 year old female with osteoporosis, labile blood pressure, hyperlipidemia and a history of breast cancer who on 04-JUN-2007 was vaccinated IM (previously reported as SC) in the left arm with a first dose of Zostavax (Oka/Merck) (lot #657675/0618U).  Concomitant therapy included AROMASIN. There was no acute illness at the time of vaccination. On approximately 08-JUN-2007 the patient experienced back pain.  On 14-JUN-2007 the patient developed 5 red lesions on her left lower back, with dermatomal distribution.  No other symptoms were noted. Medical attention was sought, the patient was treated with FAMVIR and VICODIN. There were no labs performed. On 15-JUN-2007 the patient was recovering. On 13-JUL-2007 the patient recovered. There was no product quality control complaint involved. Additional information has been requested.  Additional information is not expected.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a pharmacy student concerning a patient who during the week of 28-MAY-2007 was vaccinated SC with a dose of Zostavax (Oka/Merck).  Subsequently the patient developed shingles.  Unspecified medical attention was sought.  There was no product quality complaint involved.  The pharmacy student declined participation in the program.  No further information is available.
Age: 47.0
Sex: F
Vaccine: MNQ, VARZOS
Symptoms: Inappropriate schedule of drug administration, Injection site erythema, Injection site induration, Injection site swelling, Injection site warmth
Clinical narrative: Information has been received from a pharmacist concerning a 47 year old female with no drug reactions/allergies and an unspecified thyroid condition and a history of shingles who on 15-JUN-2007 was vaccinated with Zostavax (Oka/Merck) (657676/0619U).  Concomitant therapy included MENACTRA and CYTOMEL.  On 16-JUN-2007 the patient experienced injection site reaction.  His symptoms were described as "hard to the touch," warmth, redness and swelling.  The swollen injection site was 2.5 inches wide and 3 inches in length.  Its appearance was similar to a bee sting or a spider bite, according to the patient. No lab diagnostic studies were performed.  The patient's injection site reaction persisted.  Additional information has been requested.
Age: 73.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Pruritus, Skin warm, Urticaria
Clinical narrative: Information has been received from a health professional concerning a 73 year old female with high blood pressure, 2 diverticulosis, atrial fibrillation, degenerative disk disease and osteoporosis, an allergic reaction to tetracycline, AUGMENTIN, CIPRO and a reaction to monosodium glutamate (MSD), who on 07-JUN-2007 at 11:30 was vaccinated with Zostavax (Oka/Merck).  On 10-JUN-2007 the patient experienced itching and red hot wheals with red streaks.  No labs were done.  Subsequently, the patient recovered from itching and red hot wheals with red streaks.  No further information is expected.
Age: 75.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Pruritus, Skin warm, Urticaria
Clinical narrative: Information has been received from a health professional concerning a 75 year old female with cataracts and allergies to penicillin, aspirin, and ALTACE who on 10-MAY-2007 at 10:30 AM was vaccinated with a dose of Zostavax (Oka/Merck).  It was noted that the patient was being seen on the day of vaccination for a pre-operative physical for cataract surgery.  On 12-MAY-2007, the patient experienced "itching, redness, hot to touch, and a wheal."  No diagnostic laboratory tests were performed.  The patient recovered on an unspecified date.  No further information is expected.
Sex: F
Vaccine: VARZOS
Symptoms: Facial pain, Herpes zoster
Clinical narrative: Information has been received from a retired pediatrician concerning his wife who "about four months ago" in approximately February 2007 was vaccinated with a dose of Zostavax (Oka/Merck).  It was noted that the reporter administered the vaccine.  On 15-JUN-2007 the patient developed shingles, the patient's symptoms were right sided upper quadrant facial pain.  Unspecified medical attention was sought.  The patient was taking VALTREX as treatment.  There was no product quality complaint involved.  No further information was provided.  Additional information has been requested.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Laboratory test, Pruritus generalised, Rash
Clinical narrative: Information has been received from a 71 year old female registered nurse who on approximately 14-MAY-2007 was vaccinated with a dose of Zostavax (Oka/Merck). There was no concomitant medication. Within a day or two of vaccination, on approximately 15-MAY-2007, the patient experienced itchiness all over her body and had some rashes. The patient stated that the rashes may have developed due to the itching. She had no skin lesions. A blood test was performed (results not provided). Unspecified medical attention was sought. At the time of the report, the patient had not recovered. A product quality complaint was involved. Additional information has been requested.
Age: 71.0
Sex: F
Vaccine: VARZOS
Symptoms: Dry mouth, Headache
Clinical narrative: Information has been received from a 71 year old female with hypothyroidism and chronic dry eye and a history of ulcer and no allergies who on 15-JUN-2007 was vaccinated SC with a single dose of Zostavax (Oka/Merck). Concomitant therapy included PREVACID, estrogens, PREMARIN, SYNTHROID and RESTASIS. on 18-JUN-2007 the patient experienced a bad headache and a dry mouth. Unspecified medical attention was sought. No diagnostic laboratory tests were undertaken. At the time of the report the patient had not recovered. A product quality complaint was not involved. No further information is available.
Age: 79.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from a pharmacist concerning a 79 year old female who on 11-JUN-2007 was vaccinated with a first dose of Zostavax (Oka/Merck) at a physician's office.  There was no illness at the time of vaccination.  On approximately 13-JUN-2007, two days after vaccination the patient developed a rash.  The patient had contacted the physician and he had sent her back into the pharmacy on 18-JUN-2007 to received a MEDROL DOSEPAK.  A product quality complaint was not involved.  No further information is expected.
Age: 7.0
Sex: M
Vaccine: VARZOS
Symptoms: No adverse reaction, Wrong drug administered
Clinical narrative: Information has been received from a physician concerning a 7 year old health male child who on 19-JUN-2007 was vaccinated with Zostavax (Oka/Merck) (lot # 657558/0461U) instead of booster for Varivax (Oka/Merck) (MSD). No symptoms were reported. The physician noted that these cases of human error, not product confusion. This is one of 2 reports received from the same source. Additional information has been requested.
Age: 56.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Inflammation, Oedema peripheral, Skin warm
Clinical narrative: Information has been received from a nurse concerning her 56 year old grandmother who was vaccinated with a dose of Zostavax (Oka/Merck).  It was reported that the patient had swollen arm that was red, hot and inflamed.  The condition persisted for 5-7 days.  Unspecified medical attention was sought.  A product quality complaint was not involved.  Additional information is not available.
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Injection site induration
Clinical narrative: Information has been received from a physician concerning a female who on 25-MAY-2007 was vaccinated with a single dose of Zostavax (Oka/Merck).  It was reported that on 25-MAY-2007 the patient developed redness on her arm and hardness at the injection site. On 27-MAY-2007 the patient recovered.  Unspecified medical attention was sought.  A product quality complaint was not involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Blood pressure, Eosinophil count increased, Hypereosinophilic syndrome
Clinical narrative: Information has been received from a physician concerning a female who on 04-JUN-2007 was vaccinated with Zostavax (Oka/Merck) (lot number 657676/0619U).  Concomitant therapy included ARICEPT, PROZAC, NAMENDA, VERELAN, and PROTONIX.  Two weeks after getting the vaccine, on approximately 18-JUN-2007, the patient experienced hypereosinophil syndrome.  Medical attention was sought.  The patient's physician lowered the PROZAC dose and stopped the ARICEPT.  Subsequently the patient's eosinophil count went down.  No further information was provided.  There was no product quality complaint involved.  Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Hypoaesthesia facial, Neuralgia
Clinical narrative: Information has been received from a registered nurse concerning a male who on an unspecified date was vaccinated with a dose of Zostavax (Oka/Merck). Subsequently the patient developed nerve pain and numbness in his face. Unspecified medical attention was sought. No further information was provided. There was no product quality complaint involved. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Dyspnoea
Clinical narrative: Information has been received from a physician concerning a female who was vaccinated SC with a dose of Zostavax (Oka/Merck). It was reported that immediately after vaccination patient experienced shortness of breath. Unspecified medical attention was sought. A product quality complaint was not involved. Additional information has been requested.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Laboratory test, Rash erythematous, Rash vesicular, Skin lesion
Clinical narrative: Information has been received from a physician concerning a 70 year old female with a history of chickenpox as a child and mild case as an adult who on 07-JUN-2007 was vaccinated with 0.5 ml dose of Zostavax (Oka/Merck) (lot # 652947/1411F).  On 16-JUN-2007 the patient developed a rash on the left forearm and scapular area of the back.  The rash was described as erythematous and had clear vesicles with 20-30 lesions.  The patient did not experience pain, fever or general malaise.  The physician planned to perform a direct fluorescent antibody test for varicella and perform a zank test.  Unspecified medical attention was sought.  A product quality complaint was not involved.  Additional information is not expected.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Immunisation reaction, Laboratory test, Rash
Clinical narrative: Information has been received from a 67 year old female with "allergies", penicillin allergy and irritable bowel syndrome who on 14-JUN-2007 was vaccinated SC with a dose of Zostavax (Oka/Merck) (lot # 657559/0462U). Concomitant therapy included ZYRTEC, CLIMARA and DONNATAL. On 18-JUN-2007 the patient experienced a rash which the patient felt was shingles. The rash developed on her right side from the waist to the shoulder blades and it crossed over to the midline of her left side, also from the waist to her shoulder blade. On 29-JUN-2007 she saw her physician who did not feel that she had shingles, but had experienced a reaction to the vaccine. It was reported that the patient was recovering on an unspecified therapy. An unspecified blood test was performed (results not reported). Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Eye swelling, Rash generalised
Clinical narrative: Information has been received from a physician concerning a female (age unknown) who was vaccinated with a dose of Zostavax (Oka/Merck). Subsequently the patient's experienced eyes swelled shut and a rash on her arm and body after receiving her first dose of Zostavax (Oka/Merck). Unspecified medical attention was sought. Outcome of the patient was unknown. No product quality complaint. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a patient (age and gender unknown) who was vaccinated with a dose of Zostavax (Oka/Merck). Subsequently the patient developed shingles after receiving Zostavax (Oka/Merck). No product quality complaint. Outcome of the patient unknown. Additional information has been requested.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site vesicles, Rash
Clinical narrative: Information has been received from a physician concerning a 60 year old female who on 13-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck). On 14-JUN-2007 the patient developed redness at the injection site and it turned out a "blister like rash." The patient sought unspecified medical attention. Subsequently, the patient recovered. No other information was provided. There was no product quality complaint involved. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a registered nurse concerning a male who on an unspecified date was vaccinated subcutaneously with a dose of Zostavax. Subsequently the patient developed zoster three days after vaccination. Unspecified medical attention was sought. No further information was provided. There was no product quality complaint involved. Additional information is not expected.
Sex: U
Vaccine: VARZOS
Symptoms: Rash generalised
Clinical narrative: Information has been received from a physician concerning a patient who was vaccinated subcutaneously with a 0.65 ml dose of ZOSTAVAX. Subsequently the patient developed a rash all over the body. unspecified medical attention was sought. The patient was told to take BENADRYL. Subsequently, the patient recovered. No additional information was provided. There was no product quality complaint involved. Additional information has been requested. This is one of several reports from the same source.
Age: 61.0
Sex: F
Vaccine: TTOX, VARZOS
Symptoms: Pruritus, Skin lesion
Clinical narrative: Information has been received from a 61 year old female who on 19-JUN-2007 was vaccinated with a dose of ZOSTAVAX (657767/0740C). Concomitant therapy included tetanus toxoid, CYMBALTA and WELLBUTRIN. The patient reported that on 21-JUN-2007, she developed "half a dozen: mosquito type lesions on her torso. One of the lesions was itchy on 21-JUN-2007 and another lesion, which was the size of a small eraser was pale pink with a white middle. No fluid was leaking from the lesions. no diagnostic test were undertaken. Unspecified medical attention was sought. At the time of the report the patient had not recovered. There was no product quality complaint. A lot check was requested. A review of the initial release testing for the lot number in question was found to conform to specifications. The lot complies with the standards of the agency and was released. Additional information has been requested. This is in follow-up to report (s) previously submitted on 9/24/2007.  Information has been received from a 61 year old female who on 19-JUN-2007 was vaccinated with a dose of ZOSTAVAX (Merck) (657767/0740U).  Concomitant therapy included tetanus toxoid, CYMBALTA and WELLBUTRIN.  The patient reported that on 21-JUN-2007, she developed "half a dozen" mosquito type lesions on her torso.  One of the lesions was itchy on 21-JUN-2007 and another lesion, which was the size of a small eraser was pale pink with a white middle.  No fluid was leaking from the lesions.  No diagnostic tests were undertaken.  Unspecified medical attention was sought.  At the time of the report the patient had not recovered.  There was no product quality complaint.  In follow-up, it was reported that the vaccine was given at a different facility.  A lot check was requested.  A review of the initial release testing for the lot number in question was found to conform to specifications.  The lot complies with the standards of the Center for Biologics Evaluation and Research and was released.  No further information was available.
Age: 67.0
Sex: M
Vaccine: TTOX, VARZOS
Symptoms: Injection site erythema, Injection site reaction
Clinical narrative: Information has been received from a consumer concerning her 67 year old husband with no medical history or allergies who on 19-JUN-2007 was vaccinated with 0.5 ml dose of ZOSTAVAX (Lot # 657767/0740U). Concomitant therapy included "tetanus" and unspecified medication. On 20-JUN-2007 the patient developed injection site reaction. The reaction was described as an oval-shaped red area about 6 inches in size. Unspecified medical attention was sought. No diagnostic laboratory tests were undertaken. At the time of report the patient had not recovered. A product quality complaint was not involved. Additional information has been requested. 3/25/2010 Additional information has been received from the physician who stated that the patient received vaccine at another facility. No further information is expected.
Age: 71.0
Sex: F
Vaccine: TTOX, VARZOS
Symptoms: C-reactive protein increased, Chills, Diarrhoea, Pain, Rash
Clinical narrative: Information has been received from a physician concerning a 71 year old female who on 12-JUN-2007 was vaccinated with a 0.65 ml dose of ZOSTAVAX. Concomitant vaccination that same day included tetanus toxoid (given in the other arm). Concomitant therapy included other unspecified medication. On 16-JUN-2007 the patient experienced chills, shaking, diarrhea, general aching and she developed a chickenpox rash. Medical attention was sought, the patient consulted the physician on 19-JUN-2007. Lab studies performed included an erythrocyte sedimentation rate which was 102 and a serum C-reactive protein test which was 195.50. There was not product quality complaint involved. No further information was provided. Additional information has been requested.
Age: 71.0
Sex: F
Vaccine: TTOX, VARZOS
Symptoms: Red blood cell sedimentation rate increased, Tremor, Varicella
Clinical narrative: Information has been received from a physician concerning a 71 year old female who on 12-JUN-2007 was vaccinated with a 0.65 ml dose of ZOSTAVAX. Concomitant vaccination that same day included tetanus toxoid (given in the other arm). Concomitant therapy included other unspecified medication. On 16-JUN-2007 the patient experienced chills, shaking, diarrhea, general aching and she developed a chickenpox rash. Medical attention was sought, the patient consulted the physician on 19-JUN-2007. Lab studies performed included an erythrocyte sedimentation rate which was 102 and a serum C-reactive protein test which was 195.50. There was not product quality complaint involved. No further information was provided. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus, Rash
Clinical narrative: Information has been received from a female consumer who on an unspecified date was vaccinated with a dose of ZOSTAVAX. Subsequently she had a rash break out on her back and had some itching on her scalp. No further information was provided. No further information is available.
Sex: U
Vaccine: VARZOS
Symptoms: Varicella
Clinical narrative: Information has been received from a pharmacist concerning a patient who was vaccinated with ZOSTAVAX. The pharmacist reported that a physician's office stated a patient who was administered ZOSTAVAX developed chickenpox. As of 25-JUN-2007 the patient's chickenpox persisted. The physician had not been able to contact the patient to examine the rash or gather more information. Additional information has been requested.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Eye pain, Neuralgia
Clinical narrative: Information has been received from a registered nurse concerning a 65 year old female who on 22-JUN-2007 was vaccinated subcutaneously with a 0.65 mL dose of ZOSTAVAX. On 24-JUN-2007 the patient experienced nerve pain on left side including her eye, left nostril and underarm after the ZOSTAVAX. The patient's eye was hurting so bad she could not put her contact in. The patient had sought unspecified medical attention. As of 25-JUN-2007 the patient was recovering. Additional information has been requested.
Age: 8.0
Sex: M
Vaccine: VARZOS
Symptoms: No adverse reaction, Wrong drug administered
Clinical narrative: Information has been received from a physician concerning an 8 year old male who on 25-JUN-2007 was vaccinated with a dose of ZOSTAVAX rather than a dose of VARIVAX. No product confusion was discovered, only a medication error. The physician was not the physician that ordered or administered the vaccination. Unspecified medical attention was sought. No problems were reported. A product quality complaint was not involved. Additional information has been requested.
Age: 72.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site pain, Injection site pruritus, Injection site urticaria
Clinical narrative: Information has been received from a physician concerning a 72 year old male, who was also the patient, who on 21-JUN-2007 was vaccinated with a dose of ZOSTAVAX. There was no concomitant medication. On approximately 21-JUN-2007 the patient experienced pruritis at the injection site. On 21-JUN-2007 the patient experienced doctor received a dose of ZOSTAVAX and experienced the formation of a wheal, redness and pain at the injection. The physician was recovering from the AE's at the time of the report. Unspecified medical attention was sought. No product quality complaint. Additional information has been requested.
Age: 79.0
Sex: M
Vaccine: VARZOS
Symptoms: Neuralgia, Proctalgia, Rash
Clinical narrative: Information has been received from a physician concerning a patient who was vaccinated with a dose of ZOSTAVAX. It was reported that the patient had a perianal rash that was painful and the patient also developed nerve pain. The physician reported that the rash did not resemble shingles. It was not made clear if the rash occurred before or after vaccination. A product quality complaint was not involved. Additional information has been requested. This is in follow-up to report (s) previously submitted on 9/24/2007; 12/21/2007. Information has been received from a physician concerning a patient who was vaccinated with a dose of ZOSTAVAX (Merck). It was reported that the patient had a perianal rash that was painful and the patient also developed nerve pain. The physician reported that the rash did not resemble shingles. It was not made clear if the rash occurred before or after vaccination. A product quality complaint was not involved. Follow-up information received from a healthcare professional indicated the patient is an 80-year-old male with perianal rash, rectal pain, back pain, insomnia, pulmonary hypertension, cardiac failure congestive, coronary artery disease, type I diabetes mellitus, peripheral vascular disorder, weigh loss, edema, pruritus ani, irritated dark lesions over forearms, tinea cruris, acute upper respiratory tract infection, diarrhoea, an allergy to amoxicillin and AUGMENTIN, sulfamethoxazole and LESCOL XL who on 21-MAR-2007 at 11:45 was vaccinated subcutaneous in the right deltoid with a first dose of ZOSTAVAX (Merck) (lot # 656412/1476). On 05-FEB-2007 the patient had a perianal rash that increased after adminsitration of ZOSTAVAX vaccine (Merck). The patient has had some relief with use of LYRICA 100 (unit not reported) TID and has been evaluated by gastrointestinal "GI". At the time of the report the patient status was not recovered. Additional information has been requested.